ArticleCureus2024
Predicting Long-Term Mortality Using American College of Cardiology (ACC)/American Heart Association (AHA) Pooled Cardiovascular Risk Cohort Equations: Implications for Lipid-Lowering Therapy.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary prevention statin therapy is initiated based on the 10-year ASCVD risk estimated by the pooled cohort equations (PCEs), with treatment effectiveness monitored through low-density lipoprotein cholesterol levels. It remains uncertain whether ASCVD risk accurately predicts the mortality impact of lipid-lowering therapy. This study aims to assess the predictive performance of the PCE for mortality with and without lipid-lowering therapy and the mortality impact of lipid-lowering therapy with similar ASCVD risk.
methodsA retrospective analysis of the National Health and Nutrition Examination Survey (NHANES) (III and 1999-2008) linked to the National Death Index was conducted with propensity score matching. Cox regression and C statistic were used to determine the association between 10-year ASCVD risk and mortality.
resultsIn the matched cohort with 4,802 individuals with similar ASCVD risks, the 10-year risk of ASCVD by PCE was comparable for predicting all-cause mortality at 10 years in the lipid-lowering therapy group (area under the curve (AUC), 0.75; 95% confidence interval (CI) 0.73-0.77) and without lipid-lowering therapy (0.74; 95% CI 0.71-0.77; p = 0.50). Similarly, PCE was comparable for predicting cardiovascular mortality at 10 years in both groups (AUC, 0.75; 95% CI 0.70-0.79 versus 0.77; 95% CI 0.73-0.80; p = 0.47). Lipid-lowering therapy was significantly associated with reduced all-cause mortality (adjusted hazard ratio (HR), 0.70; 95% CI 0.61-0.82; p < 0.01) and cardiovascular mortality (adjusted HR, 0.65; 95% CI, 0.51-0.83; p < 0.01), particularly in those with a 10-year ASCVD risk of 7.5% or higher.
conclusionThe PCE comparably predicts mortality for both those on and off lipid-lowering therapy. Those on therapy have lower all-cause and cardiovascular mortality despite similar ASCVD risk. This underscores the usefulness of PCE in assessing mortality risk, both before and after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.